Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Dengvaxia and Adacel in Healthy Subjects
NCT02992418Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Dec 2016
- Primary completion
- Dec 2019
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever (2 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean Concentrations of Antibodies Against Pertussis Antigens, Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens and 1 more. Started Dec 2016; status: terminated.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02992418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992418.